A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with greater than or equal to 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy.
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
SWOG
The purpose of this study is to compare the usual approach (no more treatment or additional chemotherapy and radiation therapy after surgery or radiation therapy alone after surgery), with any effects (good or bad) of receiving one year of therapy with the experimental drug MK-3475 (also called pembrolizumab) after surgery This study will allow researchers to know whether treatment with MK-3475 (pembrolizumab) is better, the same, or worse than the usual approach alone.
Enrollment Form
This study is currently enrolling.